References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Full text
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Full text
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Aug 1;30(8):1194-220.Full text Abstract
Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2016 Jul 10;34(20):2416-27.Full text Abstract
Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Feb 10;35(5):561-64.Full text Abstract
Reference articles
1. Amin MB, Edge S, Greene, F, et al, eds. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
2. WHO Classification of Tumours Editorial Board. WHO classification of breast tumours. 5th ed. Lyon: IARC Press; 2019.
3. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23.Full text Abstract
4. Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory breast cancer: a literature review. World J Oncol. 2018 Nov;9(5-6):129-35.Full text Abstract
5. Cserni G, Charafe-Jauffret E, van Diest PJ. Inflammatory breast cancer: the pathologists' perspective. Eur J Surg Oncol. 2018 Aug;44(8):1128-34. Abstract
6. Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, et al. Paget's disease of the nipple. Breast Cancer Res Treat. 2013 Aug;141(1):1-12. Abstract
7. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49.Full text Abstract
8. National Cancer Institute. Cancer stat facts: female breast cancer [internet publication].Full text
9. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19;356(16):1670-4.Full text Abstract
10. Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1214-22.Full text Abstract
11. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001 Oct 27;358(9291):1389-99. Abstract
12. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996 Jun 1;77(11):2318-24. Abstract
13. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005 Oct;18(10):1305-20.Full text Abstract
14. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010 May;12(5):245-59. Abstract
15. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402-16.Full text Abstract
16. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000 Nov;83(10):1301-8. Abstract
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].Full text
18. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002 Apr 17;94(8):606-16.Full text Abstract
19. Endogenous Hormones and Breast Cancer Collaborative Group; Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011 Aug 23;105(5):709-22.Full text Abstract
20. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33.Full text Abstract
21. Mørch LS, Hannaford PC, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2018 Mar 29;378(13):1265-6. Abstract
22. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Sep 28;394(10204):1159-68.Full text Abstract
23. Jaiyesimi IA, Buzdar AU, Hortobagyi GN. Inflammatory breast cancer: a review. J Clin Oncol. 1992 Jun;10(6):1014-24. Abstract
24. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet. 1986 Aug;22(4):369-71. Abstract
25. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998 May;16(5):1969-77. Abstract
26. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Nov 2019 [internet publication].Full text
27. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015 Jul 20;33(21):2345-52.Full text Abstract
28. American College of Radiology. ACR appropriateness criteria: transgender breast cancer screening. 2021 [internet publication].Full text
29. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005 Mar 16;97(6):439-48.Full text Abstract
30. Bhargava S, Moen K, Qureshi SA, et al. Mammographic screening attendance among immigrant and minority women: a systematic review and meta-analysis. Acta Radiol. 2018 Nov;59(11):1285-91.Full text Abstract
31. Sung H, DeSantis CE, Fedewa SA, et al. Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. Cancer. 2019 Oct 1;125(19):3401-11.Full text Abstract
32. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401-8.Full text Abstract
33. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist. 2003;8(5):466-73.Full text Abstract
34. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA. 1993 Oct 6;270(13):1563-8. Abstract
35. Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997 May 24;349(9064):1505-10. Abstract
36. Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. Cancer. 1993 Jul 1;72(1):114-9. Abstract
37. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45.Full text Abstract
38. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May;13(1):123-5. Abstract
39. Liang M, Zhang Y, Sun C, et al. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. Mol Diagn Ther. 2018 Aug;22(4):397-407. Abstract
40. Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019 May 20;37(15):1305-15.Full text Abstract
41. Kvale G, Heuch I. Menstrual factors and breast cancer risk. Cancer. 1988 Oct 15;62(8):1625-31. Abstract
42. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol. 2007 Jul;4(7):415-23. Abstract
43. Sangaramoorthy M, Hines LM, Torres-Mejía G, et al. A pooled analysis of breastfeeding and breast cancer risk by hormone receptor status in parous Hispanic women. Epidemiology. 2019 May;30(3):449-57.Full text Abstract
44. Jeong SH, An YS, Choi JY, et al. Risk reduction of breast cancer by childbirth, breastfeeding, and their interaction in Korean women: heterogeneous effects across menopausal status, hormone receptor status, and pathological subtypes. J Prev Med Public Health. 2017 Nov;50(6):401-10.Full text Abstract
45. Nichols HB, Schoemaker MJ, Cai J, et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann Intern Med. 2019 Jan 1;170(1):22-30.Full text Abstract
46. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women's Health Initiative randomized clinical trials. JAMA Oncol. 2015 Jun;1(3):296-305.Full text Abstract
47. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020 Jul 28;324(4):369-80.Full text Abstract
48. Gartlehner G, Patel SV, Reddy S, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Nov 1;328(17):1747-65.Full text Abstract
49. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force recommendation statement. JAMA. 2022 Nov 1;328(17):1740-46.Full text Abstract
50. Schatzkin A, Jones DY, Hoover RN, et al. Alcohol consumption and breast cancer in the epidemiologic follow-up study of the first National Health and Nutrition Examination Survey. N Engl J Med. 1987 May 7;316(19):1169-73. Abstract
51. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998 Feb 18;279(7):535-40. Abstract
52. Zhang SM, Lee IM, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol. 2007 Mar 15;165(6):667-76.Full text Abstract
53. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction [internet publication].Full text
54. Suzuki R, Ye W, Rylander-Rudqvist T, et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. Natl Cancer Inst. 2005 Nov 2;97(21):1601-8.Full text Abstract
55. Zhang SM, Hankinson SE, Hunter DJ, et al. Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2004-8.Full text Abstract
56. Roychoudhuri R, Evans H, Robinson D, et al. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 2004 Aug 31;91(5):868-72. Abstract
57. Yeh JM, Lowry KP, Schechter CB, et al. Clinical benefits, harms, and cost-effectiveness of breast cancer screening for survivors of childhood cancer treated with chest radiation: a comparative modeling study. Ann Intern Med. 2020 Sep 1;173(5):331-41.Full text Abstract
58. Nelson HD, Pappas M, Cantor A, et al. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2016 Feb 16;164(4):256-67.Full text Abstract
59. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 2004 Oct 19;141(8):590-7. Abstract
60. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 2005 Jan 1;23(1):197-204.Full text Abstract
61. John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev. 1993;15(1):157-62. Abstract
62. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993 Feb 15;71(4):1258-65. Abstract
63. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985 Jan 17;312(3):146-51. Abstract
64. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21;353(3):229-37.Full text Abstract
65. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007 Jan 18;356(3):227-36.Full text Abstract
66. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst. 2007 Mar 7;99(5):386-95.Full text Abstract
67. Kerlikowske K, Sprague BL, Tosteson ANA, et al. Strategies to identify women at high risk of advanced breast cancer during routine screening for discussion of supplemental imaging. JAMA Intern Med. 2019 Jul 1;179(9):1230-9.Full text Abstract
68. American College of Radiology. ACR appropriateness criteria: supplemental breast cancer screening based on breast density. 2021 [internet publication].Full text
69. Arasu VA, Miglioretti DL, Sprague BL, et al. Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk. J Clin Oncol. 2019 Apr 20;37(12):954-63.Full text Abstract
70. Thompson CM, Mallawaarachchi I, Dwivedi DK, et al. The association of background parenchymal enhancement at breast MRI with breast cancer: a systematic review and meta-analysis. Radiology. 2019 Sep;292(3):552-61.Full text Abstract
71. Hermelink R, Leitzmann MF, Markozannes G, et al. Sedentary behavior and cancer: an umbrella review and meta-analysis. Eur J Epidemiol. 2022 May;37(5):447-60.Full text Abstract
72. Chan DSM, Abar L, Cariolou M, et al. World Cancer Research Fund International: continuous update project - systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes Control. 2019 Nov;30(11):1183-200.Full text Abstract
73. Wang YC, Lin CH, Huang SP, et al. Risk factors for female breast cancer: a population cohort study. Cancers (Basel). 2022 Feb 3;14(3):788.Full text Abstract
74. Lee J, Lee J, Lee DW, et al. Sedentary work and breast cancer risk: a systematic review and meta-analysis. J Occup Health. 2021 Jan;63(1):e12239.Full text Abstract
75. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003 Sep 10;290(10):1331-6.Full text Abstract
76. Teras LR, Patel AV, Wang M, et al. Sustained weight loss and risk of breast cancer in women ≥50 years: a pooled analysis of prospective data. J Natl Cancer Inst. 2020 Sep 1;112(9):929-37.Full text Abstract
77. Bernstein L, Henderson BE, Hanisch R, et al. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994 Sep 21;86(18):1403-8. Abstract
78. Enger SM, Bernstein L. Exercise activity, body size and premenopausal breast cancer survival. Br J Cancer. 2004 Jun 1;90(11):2138-41.Full text Abstract
79. Margolis KL, Mucci L, Braaten T, et al. Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women's Lifestyle and Health cohort study. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):27-32.Full text Abstract
80. Dixon-Suen SC, Lewis SJ, Martin RM, et al. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. Br J Sports Med. 2022 Oct;56(20):1157-70.Full text Abstract
81. Key TJ, Bradbury KE, Perez-Cornago A, et al. Diet, nutrition, and cancer risk: what do we know and what is the way forward? BMJ. 2020 Mar 5;368:m511.Full text Abstract
82. Thiebaut AC, Kipnis V, Chang SC, et al. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst. 2007 Mar 21;99(6):451-62. Abstract
83. Boyd NF, Stone J, Vogt KN, et al. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer. 2003 Nov 3;89(9):1672-85. Abstract
84. Ubago-Guisado E, Rodríguez-Barranco M, Ching-López A, et al. Evidence update on the relationship between diet and the most common cancers from the European prospective investigation into cancer and nutrition (EPIC) study: a systematic review. Nutrients. 2021 Oct 13;13(10):3582.Full text Abstract
85. Farvid MS, Barnett JB, Spence ND. Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies. Br J Cancer. 2021 Jul;125(2):284-98.Full text Abstract
86. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8;295(6):629-42.Full text Abstract
87. Martin LJ, Li Q, Melnichouk O, et al. A randomized trial of dietary intervention for breast cancer prevention. Cancer Res. 2011 Jan 1;71(1):123-33.Full text Abstract
88. Yu M, Tatalovich Z, Gibson JT, et al. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2014 Jan;25(1):81-92. Abstract
89. Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 2019 Oct;177(3):537-48. Abstract
90. Bjerkaas E, Parajuli R, Weiderpass E, et al. Smoking duration before first childbirth: an emerging risk factor for breast cancer? Results from 302,865 Norwegian women. Cancer Causes Control. 2013 Jul;24(7):1347-56.Full text Abstract
91. Catsburg C, Miller AB, Rohan TE. Active cigarette smoking and risk of breast cancer. Int J Cancer. 2015 May 1;136(9):2204-9.Full text Abstract
92. Macacu A, Autier P, Boniol M, et al. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015 Nov;154(2):213-24. Abstract
93. He Y, Si Y, Li X, et al. The relationship between tobacco and breast cancer incidence: a systematic review and meta-analysis of observational studies. Front Oncol. 2022 Sep 15;12:961970.Full text Abstract
94. Benn M, Tybjærg-Hansen A, Smith GD, et al. High body mass index and cancer risk - a Mendelian randomisation study. Eur J Epidemiol. 2016 Sep;31(9):879-92. Abstract
95. Schoemaker MJ, Nichols HB, Wright LB, et al; Premenopausal Breast Cancer Collaborative Group. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018 Nov 1;4(11):e181771.Full text Abstract
96. Wang J, Yang DL, Chen ZZ, et al. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol. 2016 Jun;42:1-8. Abstract
97. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017 Feb 28;356:j477.Full text Abstract
98. Feigelson HS, Caan B, Weinmann S, et al. Bariatric surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women. Ann Surg. 2020 Dec;272(6):1053-9. Abstract
99. Mukherjee Das A, Gogia A, Garg M, et al. Urinary concentration of endocrine-disrupting phthalates and breast cancer risk in Indian women: a case-control study with a focus on mutations in phthalate-responsive genes. Cancer Epidemiol. 2022 Aug;79:102188. Abstract
100. Ahern TP, Broe A, Lash TL, et al. Phthalate exposure and breast cancer incidence: a Danish nationwide cohort study. J Clin Oncol. 2019 Jul 20;37(21):1800-9.Full text Abstract
101. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Full text
102. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019 Nov 20;37(33):3152-65.Full text Abstract
103. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Sep 3;322(9):857-67.Full text Abstract
104. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. Abstract
105. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.Full text Abstract
106. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015 Jan;16(1):67-75.Full text Abstract
107. Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019 Apr 29;(4):CD012191.Full text Abstract
108. Nelson HD, Fu R, Zakher B, Pappas M, et al. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019 Sep 3;322(9):868-86.Full text Abstract
109. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21;295(23):2727-41.Full text Abstract
110. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010 Jun;3(6):696-706.Full text Abstract
111. Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023 Jan;34(1):33-47.Full text Abstract
112. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Aug 20;322(7):652-65.Full text Abstract
113. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Full text
114. Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014 Dec;260(6):1000-10. Abstract
115. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15;22(6):1055-62.Full text Abstract
116. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999 Jan 14;340(2):77-84.Full text Abstract
117. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 19;345(3):159-64.Full text Abstract
118. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10;26(8):1331-7.Full text Abstract
119. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75.Full text Abstract
120. Eleje GU, Eke AC, Ezebialu IU, et al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018 Aug 24;(8):CD012464.Full text Abstract
121. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015 Mar 18;107(5):djv033. Abstract
122. Terry MB, Daly MB, Phillips KA, et al. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J Natl Cancer Inst. 2019 Mar 1;111(3):331-4.Full text Abstract
123. Ho CM, Mak CK, Lau Y, et al. Skin involvement in invasive breast carcinoma: safety of skin-sparing mastectomy. Ann Surg Oncol. 2003 Mar;10(2):102-7. Abstract
124. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):143-7. Abstract
125. Fisher ER, Gregorio RM, Fisher B, et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975 Jul;36(1):1-85.Full text Abstract
126. American College of Radiology. ACR practice parameter for the performance of screening and diagnostic mammography. 2018 [internet publication].Full text
127. American College of Radiology. ACR appropriateness criteria: imaging of the axilla. 2021 [internet publication].Full text
128. Moss HA, Britton PD, Flower CD, et al. How reliable is modern breast imaging in differentiating benign from malignant breast lesions in the symptomatic population? Clin Radiol. 1999 Oct;54(10):676-82. Abstract
129. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast cancer screening recommendations inclusive of all women at average risk: update from the ACR and society of breast imaging. J Am Coll Radiol. 2021 Sep;18(9):1280-8.Full text Abstract
130. Expert Panel on Breast Imaging, Weinstein SP, Slanetz PJ, et al. ACR Appropriateness Criteria® supplemental breast cancer screening based on breast density. J Am Coll Radiol. 2021 Nov;18(11s):S456-73.Full text Abstract
131. Chen HL, Zhou JQ, Chen Q, et al. Comparison of the sensitivity of mammography, ultrasound, magnetic resonance imaging and combinations of these imaging modalities for the detection of small (≤2 cm) breast cancer. Medicine (Baltimore). 2021 Jul 2;100(26):e26531.Full text Abstract
132. American College of Radiology. ACR practice parameter for the performance of a breast ultrasound examination. 2021 [internet publication].Full text
133. Flobbe K, Bosch AM, Kessels AG, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med. 2003 May 26;163(10):1194-9.Full text Abstract
134. Expert Panel on Breast Imaging, Hayward JH, Linden OE, et al. ACR Appropriateness Criteria® monitoring response to neoadjuvant systemic therapy for breast cancer: 2022 Update. J Am Coll Radiol. 2023 May;20(5s):S125-45.Full text Abstract
135. Bin L, Huihui Y, Weiping Y, et al. Value of three-dimensional ultrasound in differentiating malignant from benign breast tumors: a systematic review and meta-analysis. Ultrasound Q. 2019 Mar;35(1):68-73.Full text Abstract
136. American College of Radiology. ACR appropriateness criteria: imaging after mastectomy and breast reconstruction. 2020 [internet publication].Full text
137. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 8;292(22):2735-42.Full text Abstract
138. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010 Feb 13;375(9714):563-71. Abstract
139. Diao W, Tian F, Jia Z. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer. Eur J Radiol. 2018 Aug;105:1-7. Abstract
140. Ljung BM, Drejet A, Chiampi N, et al. Diagnostic accuracy of fine-needle aspiration biopsy is determined by physician training in sampling technique. Cancer. 2001 Aug 25;93(4):263-8.Full text Abstract
141. Allison KH, Hammond ME, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020 Apr 20;38(12):1346-66.Full text Abstract
142. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023 Aug 1;41(22):3867-72.Full text Abstract
143. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015 Nov 19;373(21):2005-14.Full text Abstract
144. Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw. 2013 Feb 1;11(2):174-82.Full text Abstract
145. Harbeck N, Sotlar K, Wuerstlein R, et al. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev. 2014 Apr;40(3):434-44. Abstract
146. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019 Jun 20;380(25):2395-405.Full text Abstract
147. Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022 Jun 1;40(16):1816-37.Full text Abstract
148. National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Dec 2018 [internet publication].Full text
149. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26.Full text Abstract
150. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018 Jul 12;379(2):111-21.Full text Abstract
151. Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol. 2019 Sep 30;6(3):367-74.Full text Abstract
152. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021 Dec 16;385(25):2336-47.Full text Abstract
153. Seltzer MH, Perloff LJ, Kelley RI, et al. The significance of age in patients with nipple discharge. Surg Gynecol Obstet. 1970 Sep;131(3):519-22. Abstract
154. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980 Jun 15;45(12):2917-24. Abstract
155. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018 Aug;170(3):647-56.Full text Abstract
156. Fiorca JV. Fibrocystic changes. Obstet Gynecol Clin North Am. 1994 Sep;21(3):445-52. Abstract
157. Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35. Abstract
158. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4;(6):CD001877.Full text Abstract
159. US Preventive Services Task Force. Breast cancer: screening. US Preventive Services Task Force recommendation statement. Jan 2016 [internet publication].Full text
160. Committee on Practice Bulletins - Gynecology. Practice bulletin number 179: breast cancer risk assessment and screening in average-risk women. Obstet Gynecol. 2017 Jul;130(1):e1-16. Abstract
161. US Preventive Services Task Force. Breast cancer: screening. Draft recommendation statement. May 2023 [internet publication].Full text
162. Oeffinger KC, Fontham ET, Etzioni R, et al; American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614.Full text Abstract
163. Aristokli N, Polycarpou I, Themistocleous SC, et al. Comparison of the diagnostic performance of Magnetic Resonance Imaging (MRI), ultrasound and mammography for detection of breast cancer based on tumor type, breast density and patient's history: A review. Radiography (Lond). 2022 Aug;28(3):848-56. Abstract
164. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. Abstract
165. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012 Apr 4;307(13):1394-404.Full text Abstract
166. American College of Obstetrics and Gynecology. Committee opinion no. 625: management of women with dense breasts diagnosed by mammography. Obstet Gynecol. 2015 Mar;125(3):750-1.Full text Abstract
167. US Food and Drug Administration. Important information: final rule to amend the Mammography Quality Standards Act (MQSA). Jan 2024 [internet publication].Full text
168. American College of Obstetricians and Gynecologists. Practice advisory to committee opinion no. 625: management of women with dense breasts diagnosed by mammography. Apr 2023 [internet publication]Full text
169. Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-14. Abstract
170. Bobo JK, Lee NC, Thames SF, et al. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst. 2000 Jun 21;92(12):971-6.Full text Abstract
171. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019 Oct;26(10):3025-31.Full text Abstract
172. Centers for Disease Control and Prevention. Hereditary breast and ovarian cancer (HBOC) phase 2. Mar 2014 [internet publication].Full text
173. Committee on Gynecologic Practice. ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018 Jan;131(1):e31-4.Full text Abstract
174. American College of Radiology. ACR appropriateness criteria: imaging after breast surgery. 2022 [internet publication].Full text Abstract
175. Smith-Gagen J, Carrillo JE, Ang A, et al. Practices that reduce the Latina survival disparity after breast cancer. J Womens Health (Larchmt). 2013 Nov;22(11):938-46. Abstract
176. Buist DS, Bosco JL, Silliman RA, et al. Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer. Breast Cancer Res Treat. 2013 Nov;142(1):153-63. Abstract
177. American College of Radiology. ACR appropriateness criteria: palpable breast masses. 2022 [internet publication].Full text
178. Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020 Jun 1;38(16):1849-63.Full text Abstract
179. American College of Radiology. ACR appropriateness criteria: stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. 2019 [internet publication].Full text
180. Mainiero MB, Moy L, Baron P, et al; Expert Panel on Breast Imaging. ACR appropriateness criteria®: breast cancer screening. J Am Coll Radiol. 2017 Nov;14(11S):S383-90.Full text Abstract
181. American College of Radiology. ACR appropriateness criteria: conservative surgery and radiation - stage I and II breast cancer. 2015 [internet publication].Full text
182. Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022 Nov;33(11):1097-118.Full text Abstract
183. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec;31(12):1623-49.Full text Abstract
184. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Aug 1;30(8):1194-220.Full text Abstract
185. Migowski A, Silva GAE, Dias MBK, et al. Guidelines for early detection of breast cancer in Brazil. II - New national recommendations, main evidence, and controversies. Cad Saude Publica. 2018 Jun 21;34(6):e00074817.Full text Abstract
186. Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2016 Jul 10;34(20):2416-27.Full text Abstract
187. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 Aug 1;28(8):1700-12.Full text Abstract
188. Giordano SH, Freedman RA, Somerfield MR, et al. Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update. J Clin Oncol. 2022 Jan 20;40(3):307-9.Full text Abstract
189. Royce M, Osgood C, Mulkey F, et al. FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer. J Clin Oncol. 2022 Apr 10;40(11):1155-62.Full text Abstract
190. Korde LA, Somerfield MR, Hershman DL, et al. Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 May 20;40(15):1696-8.Full text Abstract
191. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020 Feb 27;382(9):810-21.Full text Abstract
192. Tung NM, Zakalik D, Somerfield MR, et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol. 2021 Sep 10;39(26):2959-61.Full text Abstract
193. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021 Jun 24;384(25):2394-405.Full text Abstract
194. Emens LA, Adams S, Cimino-Mathews A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 Aug;9(8):e002597.Full text Abstract
195. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987-98.Full text Abstract
196. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41.Full text Abstract
197. Havel L, Naik H, Ramirez L, et al. Impact of the SSO-ASTRO margin guideline on rates of re-excision after lumpectomy for breast cancer: a meta-analysis. Ann Surg Oncol. 2019 May;26(5):1238-44. Abstract
198. Kuerer HM, Gwyn K, Ames FC, et al. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery. 2002 Jan;131(1):108-10. Abstract
199. Framarino-Dei-Malatesta M, Sammartino P, Napoli A. Does anthracyclinebased chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus? BMC Cancer. 2017 Nov 21;17(1):777.Full text Abstract
200. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol. 2004 Jan;15(1):146-50.Full text Abstract
201. Murthy RK, Theriault RL, Barnett CM, et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014 Dec 30;16(6):500.Full text Abstract
202. Gieni M, Avram R, Dickson L, et al. Local breast cancer recurrence after mastectomy and immediate breast reconstruction for invasive cancer: a meta-analysis. Breast. 2012 Jun;21(3):230-6. Abstract
203. Newman LA, Kuerer HM, Hunt KK, et al. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol. 1998 Oct-Nov;5(7):620-6. Abstract
204. Medina-Franco H, Vasconez LO, Fix RJ, et al. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg. 2002 Jun;235(6):814-9.Full text Abstract
205. Agha RA, Al Omran Y, Wellstead G, et al. Systematic review of therapeutic nipple-sparing versus skin-sparing mastectomy. BJS Open. 2019 Apr;3(2):135-45.Full text Abstract
206. Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020 Jun 20;38(18):2080-106.Full text Abstract
207. Sadok N, Krabbe-Timmerman IS, de Bock GH, et al. The effect of smoking and body mass index on the complication rate of alloplastic breast reconstruction. Scand J Surg. 2020 Jun;109(2):143-50. Abstract
208. O'Neill AC, Sebastiampillai S, Zhong T, et al. Increasing body mass index increases complications but not failure rates in microvascular breast reconstruction: a retrospective cohort study. J Plast Reconstr Aesthet Surg. 2019 Sep;72(9):1518-24. Abstract
209. Duggal CS, Grudziak J, Metcalfe DB, et al. The effects of breast size in unilateral postmastectomy breast reconstruction. Ann Plast Surg. 2013 May;70(5):506-12. Abstract
210. Hart A, Funderburk CD, Chu CK, et al. The impact of diabetes mellitus on wound healing in breast reconstruction. Ann Plast Surg. 2017 Mar;78(3):260-3. Abstract
211. Wang K, Dai Y, Pan Y, et al. Local-regional recurrence risk after autologous fat grafting in breast cancer patients: a systematic review and meta-analysis. J Surg Oncol. 2020 Mar;121(3):435-40. Abstract
212. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003 Aug 7;349(6):546-53.Full text Abstract
213. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010 Apr;251(4):595-600. Abstract
214. Glechner A, Wöckel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013 Mar;49(4):812-25. Abstract
215. Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013 Jan;20(1):120-7. Abstract
216. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010 Oct;11(10):927-33.Full text Abstract
217. Julian TB, Anderson SJ, Krag DN, et al. 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. Paper presented at: 2013 ASCO Annual Meeting I. J Clin Oncol. 2013 May 20;31(15 suppl):1000.Full text
218. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006 May 3;98(9):599-609.Full text Abstract
219. Bromham N, Schmidt-Hansen M, Astin M, et al. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561.Full text Abstract
220. Choosing Wisely; Society of Surgical Oncology. Five things physicians and patients should question. Jul 2021 [internet publication].Full text
221. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002 May 15;94(10):2542-51.Full text Abstract
222. Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Feb 10;35(5):561-64.Full text Abstract
223. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32. Abstract
224. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 Feb 9;305(6):569-75. Abstract
225. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017 Sep 12;318(10):918-26.Full text Abstract
226. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303-10. Abstract
227. Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017 Apr;43(4):672-9. Abstract
228. Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol. 2007 Jan 29;5:10.Full text Abstract
229. Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol. 2014 Aug;21(8):2506-11. Abstract
230. Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1932-47. Abstract
231. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022 Feb 10;386(6):556-67.Full text Abstract
232. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-30. Abstract
233. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Abstract
234. Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019 Mar;269(3):432-42.Full text Abstract
235. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008 May-Jun;14(3):250-4. Abstract
236. Gentilini O, Cremonesi M, Trifirò G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004 Sep;15(9):1348-51.Full text Abstract
237. Keleher A, Wendt R 3rd, Delpassand E, et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004 Nov-Dec;10(6):492-5. Abstract
238. Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015 Aug 1;121(15):2544-52.Full text Abstract
239. Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015 Jun;220(6):1063-9. Abstract
240. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021 May 1;39(13):1485-505.Full text Abstract
241. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27-39.Full text Abstract
242. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002.Full text Abstract
243. van Nes JG, Putter H, Julien JP, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009 May;115(1):101-13. Abstract
244. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001 Dec 1;(30):96-102.Full text Abstract
245. Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10;30(26):3242-9.Full text Abstract
246. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. Abstract
247. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81.Full text Abstract
248. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20;30(15):1796-804.Full text Abstract
249. Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar;84:101965.Full text Abstract
250. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 1;23(16):3686-96.Full text Abstract
251. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83. Abstract
252. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009 May 20;27(15):2474-81. Abstract
253. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008 Jan 1;26(1):44-53.Full text Abstract
254. Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008 Jan 16;100(2):121-33.Full text Abstract
255. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14.Full text Abstract
256. Shao N, Wang S, Yao C, et al. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. Breast. 2012 Jun;21(3):389-93. Abstract
257. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71.Full text Abstract
258. Qin YY, Li H, Guo XJ, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One. 2011 Nov 1;6(11):e26946.Full text Abstract
259. Peto R, Davies C, Godwin J, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012 Feb 4;379(9814):432-44. Abstract
260. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10;35(23):2647-55.Full text Abstract
261. Willson ML, Burke L, Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019 Sep 2;(9):CD004421.Full text Abstract
262. Eiermann W, Pienkowski T, Crown J, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84.Full text Abstract
263. Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053-65.Full text Abstract
264. Zaheed M, Wilcken N, Willson ML, et al. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019 Feb 18;(2):CD012873.Full text Abstract
265. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Abstract
266. Goldhirsch A, Colleoni M, Coates AS, et al; International Breast Cancer Study Group (IBCSG). Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? Ann Oncol. 1998 May;9(5):489-93.Full text Abstract
267. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7.Full text Abstract
268. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide Is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. Abstract
269. Ding W, Li Z, Wang C, et al. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2018 Oct;97(42):e12908.Full text Abstract
270. Isaac N, Panzarella T, Lau A, et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer. 2002 Aug 15;95(4):696-703.Full text Abstract
271. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010 Jan 30;375(9712):377-84. Abstract
272. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. Abstract
273. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84.Full text Abstract
274. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800. Abstract
275. Swain SM, Ewer MS, Viale G, et al; BERENICE Study Group. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018 Mar 1;29(3):646-53.Full text Abstract
276. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018 Jan;89:27-35. Abstract
277. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-26. Abstract
278. Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol. 2019 Sep 1;37(25):2206-16.Full text Abstract
279. Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 2020 Mar 1;6(3):e193692.Full text Abstract
280. Chen S, Liang Y, Feng Z, et al. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC Cancer. 2019 Oct 21;19(1):973.Full text Abstract
281. van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Dec;19(12):1630-40. Abstract
282. Jackisch C, Hegg R, Stroyakovskiy D, et al. HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. Eur J Cancer. 2016 Jul;62:62-75.Full text Abstract
283. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-205.Full text Abstract
284. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet. 2019 Jun 29;393(10191):2591-8. Abstract
285. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019 Feb 14;380(7):617-28.Full text Abstract
286. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. Jun 2023 [internet publication].Full text
287. Morgan J, Wyld L, Collins KA. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2014 May 16;(5):CD004272.Full text
288. Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016 Nov 1;2(11):1477-86.Full text Abstract
289. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. Jul 2018 [internet publication].Full text
290. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol. 2001 Jun 15;19(12):3103-10. Abstract
291. Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.Full text Abstract
292. Nitz U, Gluz O, Clemens M, et al. West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019 Apr 1;37(10):799-808. Abstract
293. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12;295(14):1658-67.Full text Abstract
294. Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO endorsement of the Cancer Care Ontario guideline. J Clin Oncol. 2019 Aug 1;37(22):1965-77.Full text Abstract
295. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016 Aug 25;375(8):717-29.Full text Abstract
296. Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017 Oct;165(3):573-83.Full text Abstract
297. Esserman LJ, Yau C, Thompson CK, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol. 2017 Nov 1;3(11):1503-10.Full text Abstract
298. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-59.Full text Abstract
299. Desmedt C, Fornili M, Clatot F, et al. Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index. J Clin Oncol. 2020 Sep 1;38(25):2883-91. Abstract
300. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019 Apr 6;393(10179):1440-52.Full text Abstract
301. Green AK, Aviki EM, Matsoukas K, et al. Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2018 Nov;172(2):247-63.Full text Abstract
302. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83.Full text Abstract
303. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52.Full text Abstract
304. Shen Y, Fujii T, Ueno NT, et al. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019 Jan;173(1):1-9.Full text Abstract
305. Wilson FR, Coombes ME, Brezden-Masley C, et al. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev. 2018 Nov 14;7(1):191.Full text Abstract
306. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-31.Full text Abstract
307. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367-77. Abstract
308. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-700. Abstract
309. Tolaney S, Barry WT, Dang CT, et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Res. 2013;73(suppl 24):abstract S1-04.Full text
310. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134-41.Full text Abstract
311. Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019 Aug 1;37(22):1868-75.Full text Abstract
312. Pivot X, Romieu G, Debled M, et al; PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013 Jul;14(8):741-8. Abstract
313. Goldvaser H, Korzets Y, Shepshelovich D, et al. Deescalating adjuvant trastuzumab in HER2-positive early-stage breast cancer: a systemic review and meta-analysis. JNCI Cancer Spectr. 2019 May 11;3(2):pkz033.Full text Abstract
314. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021-8. Abstract
315. Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018 Sep 1;4(9):1199-206.Full text Abstract
316. Chen L, Zhou W, Hu X, et al. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2019 May;75:12-9.Full text Abstract
317. Inno A, Barni S, Ghidini A, et al. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019 Jan;173(2):247-54. Abstract
318. Migliavacca Zucchetti B, Nicolò E, Curigliano G. Biosimilars for breast cancer. Expert Opin Biol Ther. 2019 Oct;19(10):1015-21. Abstract
319. Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. J Clin Oncol. 2021 Feb 20;39(6):685-93.Full text Abstract
320. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19;374(9707):2055-63. Abstract
321. Alkner S, Bendahl PO, Ferno M, et al. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer. 2009 Sep;45(14):2496-502. Abstract
322. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018 Jul 12;379(2):122-37.Full text Abstract
323. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18.Full text Abstract
324. Kim HA, Lee JW, Nam SJ, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial. J Clin Oncol. 2020 Feb 10;38(5):434-43.Full text Abstract
325. Bui KT, Willson ML, Goel S, et al. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev. 2020 Mar 6;(3):CD013538.Full text Abstract
326. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16.Full text Abstract
327. Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013 Jun 20;31(8) suppl: abstr 5.Full text
328. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017 Nov 9;377(19):1836-46.Full text Abstract
329. Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018 Jul 1;36(19):1981-90.Full text Abstract
330. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92.Full text Abstract
331. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. Abstract
332. Forbes JF, Cuzick J, Buzdar A, et al; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 Jan;9(1):45-53. Abstract
333. Joerger M, Thurlimann B. Update of the BIG 1-98 Trial: where do we stand? Breast. 2009 Oct;18 Suppl 3:S78-82. Abstract
334. Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019 Jan 10;37(2):105-14.Full text Abstract
335. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016 Jul 21;375(3):209-19.Full text Abstract
336. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019 Feb 10;37(5):423-38.Full text Abstract
337. Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):88-99.Full text Abstract
338. Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 Jul 1;113(7):808-19.Full text Abstract
339. Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021 Dec;32(12):1571-81.Full text Abstract
340. Darby S, McGale P, Correa C, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707-16.Full text Abstract
341. Sedlmayer F, Sautter-Bihl ML, Budach W, et al. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013 Oct;189(10):825-33.Full text Abstract
342. Korzets Y, Fyles A, Shepshelovich D, et al. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019 Jun;175(3):531-45. Abstract
343. Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019 Dec 14;394(10215):2155-64.Full text Abstract
344. Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017 Mar-Apr;7(2):73-9. Abstract
345. Kirby AM. Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial? Br J Radiol. 2018 May;91(1085):20170565.Full text Abstract
346. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015 Jul 23;373(4):307-16. Abstract
347. Whelan TJ, Olivotto IA, Levine MN. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015 Nov 5;373(19):1878-9. Abstract
348. Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016 Feb 1;34(4):314-20.Full text Abstract
349. Kindts I, Laenen A, Depuydt T, et al. Tumour bed boost radiotherapy for women after breast-conserving surgery. Cochrane Database Syst Rev. 2017 Nov 6;(11):CD011987.Full text Abstract
350. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Oct;14(11):1086-94.Full text Abstract
351. Bentzen SM, Agrawal RK, Aird EG, et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008 Apr;9(4):331-41.Full text Abstract
352. Bentzen SM, Agrawal RK, Aird EG, et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008 Mar 29;371(9618):1098-107.Full text Abstract
353. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010 Feb 11;362(6):513-20.Full text Abstract
354. Hickey BE, James ML, Lehman M, et al. Hypofractionated radiation therapy for early breast cancer. Cochrane Database Syst Rev. 2016 Jul 18;(7):CD003860.Full text Abstract
355. Andrade TRM, Fonseca MCM, Segreto HRC, et al. Meta-analysis of long-term efficacy and safety of hypofractionated radiotherapy in the treatment of early breast cancer. Breast. 2019 Dec;48:24-31. Abstract
356. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020 May 23;395(10237):1613-26.Full text Abstract
357. Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020 Oct 1;38(28):3261-72.Full text Abstract
358. Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1;27(16):2638-44. Abstract
359. Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016 Dec 20;34(36):4431-42.Full text Abstract
360. Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000 Mar;18(6):1220-9. Abstract
361. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.Full text Abstract
362. McGale P, Taylor C, Correa C, et al; EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383(9935):2127-35.Full text Abstract
363. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):352-60. Abstract
364. Budach W, Matuschek C, Bölke E, et al. DEGRO practical guidelines for radiotherapy of breast cancer V: therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol. 2015 Aug;191(8):623-33.Full text Abstract
365. Rutgers EJ, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023). Paper presented at: 2018 San Antonio Breast Cancer Symposium. 2018. San Antonio, TX. Cancer Res. 2019 Feb;79(4 Suppl):Abstract GS4-01.Full text
366. Poleszczuk J, Luddy K, Chen L, et al. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 2017 Jun 30;19(1):75.Full text Abstract
367. Jensen KE, Soril LJJ, Stelfox HT, et al. Side effects associated with the use of intensity-modulated radiation therapy in breast cancer patients undergoing adjuvant radiation therapy: a systematic review and meta-analysis. J Med Imaging Radiat Sci. 2017 Dec;48(4):402-13. Abstract
368. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015 Mar;51(4):451-63. Abstract
369. Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence Trial. J Clin Oncol. 2020 Dec 10;38(35):4175-83.Full text Abstract
370. Harness JK, Davies K, Via C, et al. Meta-analysis of local invasive breast cancer recurrence after electron intraoperative radiotherapy. Ann Surg Oncol. 2018 Jan;25(1):137-47. Abstract
371. Kanis JA, McCloskey EV, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999 Mar;79(7-8):1179-81. Abstract
372. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006 Aug;21(8):1215-23.Full text Abstract
373. Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019 Nov 1;37(31):2916-46.Full text Abstract
374. Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 2022 Mar 1;40(7):787-800.Full text Abstract
375. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012 Mar 1;118(5):1192-201. Abstract
376. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13;365(15):1396-405. Abstract
377. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013 Feb;24(2):398-405. Abstract
378. O'Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017 Oct 30;(10):CD003474.Full text Abstract
379. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):339-51. Abstract
380. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015 Oct 3;386(10001):1353-61.Full text Abstract
381. Gralow JR, Barlow WE, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707.Full text Abstract
382. Friedl TWP, Fehm T, Müller V, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial. JAMA Oncol. 2021 Aug 1;7(8):1149-57.Full text Abstract
383. Food and Drug Administration. FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab). Nov 2022 [internet publication].Full text
384. American College of Radiology. ACR appropriateness criteria: local-regional recurrence (LRR) and salvage surgery - breast cancer. 2013 [internet publication].Full text
385. Aebi S, Gelber S, Anderson SJ, et al; CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb;15(2):156-63.Full text Abstract
386. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6.Full text Abstract
387. Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018 Feb 1;29(2):405-17.Full text Abstract
388. Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer. A review of 104 cases. Ann Surg. 1992 May;215(5):451-7.Full text Abstract
389. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Ann Surg Oncol. 2013 May;20(5):1545-50. Abstract
390. Sauder CAM, Bateni SB, Davidson AJ, et al. Breast conserving surgery compared with mastectomy in male breast cancer: a brief systematic review. Clin Breast Cancer. 2020 Jun;20(3):e309-14.Full text Abstract
391. Rusby JE, Smith BL, Dominguez FJ, et al. Sentinel lymph node biopsy in men with breast cancer: a report of 31 consecutive procedures and review of the literature. Clin Breast Cancer. 2006 Dec;7(5):406-10. Abstract
392. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005 Dec 1;104(11):2359-64.Full text Abstract
393. Cimmino VM, Degnim AC, Sabel MS, et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol. 2004 May 1;86(2):74-7. Abstract
394. Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct;203(4):475-80. Abstract
395. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992 Feb;65(2):252-4. Abstract
396. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013 Jan;137(2):465-70. Abstract
397. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92.Full text Abstract
398. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022 Mar;33(3):321-9.Full text Abstract
399. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Abstract
400. Untch M, von Minckwitz G, Gerber B, et al. Survival analysis after neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer in the GeparQuinto (G5) study (GBG 44). J Clin Oncol. 2018 May 1;36(13):1308-16. Abstract
401. ClinicalTrials.gov. Evaluation of IPI-549 combined with front-line treatments in patients with triple-negative breast cancer or renal cell carcinoma (MARIO-3). Apr 2022 [internet publication].Full text
402. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.Full text Abstract
403. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018 May-Jun;8(3):145-52.Full text Abstract
404. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016 May 10;34(14):1689-701.Full text Abstract
405. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20;32(21):2255-69.Full text Abstract
406. Khatcheressian JL, Hurley P, Bantug E, et al; American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1;31(7):961-5.Full text Abstract
407. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017 Mar 23;7:1-12.Full text Abstract
408. Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, et al. SEOM clinical guidelines in early stage breast cancer (2018). Clin Transl Oncol. 2019 Jan;21(1):18-30.Full text Abstract
409. Grossmann M, Ramchand SK, Milat F, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf). 2018 Sep;89(3):280-96.Full text Abstract
410. Wang F, Shu X, Meszoely I, et al. Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol. 2019 Sep 19;5(11):1589-96.Full text Abstract
411. Huang W, Ran R, Shao B, et al. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019 Nov;178(1):17-33. Abstract
412. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018 Jun 1;110(6):560-7.Full text Abstract
413. Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast eancers. J Clin Oncol. 2019 Mar 1;37(7):559-69.Full text Abstract
414. Kovács A, Stenmark Tullberg A, Werner Rönnerman E, et al. Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial. J Clin Oncol. 2019 May 10;37(14):1179-87.Full text Abstract
415. Li S, He Y, Li C, et al. The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: a meta-analysis. Medicine (Baltimore). 2020 Mar;99(10):e19345.Full text Abstract
416. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104-10. Abstract
417. Louwman WJ, Janssen-Heijnen ML, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer. 2005 Mar;41(5):779-85. Abstract
418. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997 Jan;15(1):103-9. Abstract
419. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Oct 1;35(28):3240-61.Full text Abstract
420. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199-212.Full text Abstract
421. Carroll J, Protani M, Walpole E, et al. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Res Treat. 2012 Nov;136(2):323-30. Abstract
422. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].Full text
423. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718-29. Abstract
424. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016 Jan;2(1):65-73.Full text Abstract
425. Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977 Feb;62(2):200-8. Abstract
426. Ryberg M, Nielsen DL, Cortese G, et al. Epirubicin (E) cardiac toxicity: a retrospective analysis of 1,097 patients (pts) treated for metastatic breast cancer (MBC). Paper presented at: 2007 ASCO Annual Meeting. J Clin Oncol. 2007;25(18S-June 20 suppl):1029.Full text
427. Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009 Oct;15(8):651-7. Abstract
428. Yu AF, Flynn JR, Moskowitz CS, et al. Long-term cardiopulmonary consequences of treatment-induced cardiotoxicity in survivors of ERBB2-positive breast cancer. JAMA Cardiol. 2020 Jan 15;5(3):309-17. Abstract
429. Kaboré EG, Guenancia C, Vaz-Luis I, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med. 2019 Dec 23;16(12):e1002989.Full text Abstract
430. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133-9. Abstract
431. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003 Apr 1;21(7):1195-204. Abstract
432. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007 Sep 1;25(25):3871-6. Abstract
433. Okwuosa TM, Morgans A, Rhee JW, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021 Jun;14(3):e000082.Full text Abstract
434. Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018 Jan 1;110(1).Full text Abstract
435. Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018 Oct 8;363:k3845.Full text Abstract
436. Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017 Mar 1;28(3):487-96.Full text Abstract
437. He Y, Zhang J, Shen G, et al. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019 Oct 29;20(1):62.Full text Abstract
438. Haque R, Shi J, Schottinger JE, et al. Cardiovascular disease after aromatase inhibitor use. JAMA Oncol. 2016 Dec 1;2(12):1590-7.Full text Abstract
439. Khosrow-Khavar F, Filion KB, Bouganim N, et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation. 2020 Feb 18;141(7):549-59.Full text Abstract
440. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007 Mar 1;25(7):829-36.Full text Abstract
441. Price J, Purtell JR. Prevention and treatment of lymphedema after breast cancer. Am J Nurs. 1997 Sep;97(9):34-7. Abstract
442. McNeely ML, Campbell K, Ospina M, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005211.Full text Abstract
443. Markkula SP, Leung N, Allen VB, et al. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Cochrane Database Syst Rev. 2019 Feb 19;(2):CD011433.Full text Abstract
444. Co M, Lee A, Kwong A. Cutaneous angiosarcoma secondary to lymphoedema or radiation therapy - a systematic review. Clin Oncol (R Coll Radiol). 2019 Apr;31(4):225-31. Abstract
445. Smile TD, Tendulkar R, Schwarz G, et al. A review of treatment for breast cancer-related lymphedema: paradigms for clinical practice. Am J Clin Oncol. 2018 Feb;41(2):178-90. Abstract
446. Dayes IS, Whelan TJ, Julian JA, et al. Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol. 2013 Oct 20;31(30):3758-63.Full text Abstract
447. Cianfrocca M, Flatters SJ, Bennett GJ, et al. Peripheral neuropathy in a woman with breast cancer. J Pain. 2006 Jan;7(1):2-10. Abstract
448. van Deventer H, Bernard S. Use of gabapentin to treat taxane-induced myalgias. J Clin Oncol. 1999 Jan;17(1):434-5.Full text Abstract
449. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother. 2005 Jun;6(7):1095-106. Abstract
450. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000 Dec 16;356(9247):2059-63. Abstract
451. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.Full text Abstract
452. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005 Sep 3-9;366(9488):818-24. Abstract
453. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000 May 16;132(10):788-93. Abstract
454. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008 Apr 1;26(10):1650-6.Full text Abstract
455. Wang K, Yee C, Tam S, et al. Prevalence of pain in patients with breast cancer post-treatment: A systematic review. Breast. 2018 Dec;42:113-27. Abstract
456. Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016 Oct 4;188(14):E352-61.Full text Abstract
457. Khan JS, Ladha KS, Abdallah F, et al. Treating persistent pain after breast cancer surgery. Drugs. 2020 Jan;80(1):23-31. Abstract
458. Moschetti I, Cinquini M, Lambertini M, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2016 May 27;2016(5):CD001768.Full text Abstract
459. Lu WL, Jansen L, Post WJ, et al. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009 Apr;114(3):403-12. Abstract
460. Choosing Wisely; American Society for Radiation Oncology. Follow-up mammograms following radiotherapy for breast conservation. Sep 2021 [internet publication].Full text
461. Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011 Jan;47(1):74-83. Abstract
462. Partridge AH, Niman SM, Ruggeri M, et al. Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct;59:327-38.Full text Abstract
463. Spronk I, Schellevis FG, Burgers JS, et al. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast. 2018 Jun;39:70-9. Abstract
464. Akdeniz D, Schmidt MK, Seynaeve CM, et al. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2019 Apr;44:1-14. Abstract
465. Rock CL, Thomson CA, Sullivan KR, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022 May;72(3):230-62.Full text Abstract
466. Soares Falcetta F, de Araújo Vianna Träsel H, de Almeida FK, et al. Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2018 Aug;170(3):455-76. Abstract
467. Chlebowski RT, Aragaki AK, Anderson GL, et al. Dietary modification and breast cancer mortality: long-term follow-up of the Women's Health Initiative randomized trial. J Clin Oncol. 2020 May 1;38(13):1419-28. Abstract
468. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer - systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014 Oct;25(10):1901-14.Full text Abstract
469. Mauri D, Valachis A, Polyzos NP, et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw. 2010 Mar;8(3):279-86. Abstract
Use of this content is subject to our disclaimer